Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with triple-negative breast cancer (a specific type of breast cancer) confirmed through a lab test on a tissue or cell sample.
- People whose triple-negative breast cancer has come back in the same area or spread to other parts of the body, and has continued to grow after at least one previous cancer treatment.
- People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines.
- People who are either fully active or have mild limits on physical activity but are still able to do light work (confirm with trial site what this means for individual circumstances).
- People who are expected to live for more than 3 months.
- People whose blood tests show that their organs and blood cell levels are working well enough to participate.
- People who are willing to read and sign a consent form agreeing to take part.
Who may not be able to join:
- People who have had a serious allergic reaction to similar medicines in the past, including antibody-based treatments, or who have a medical reason they cannot take the study drug.
- People who need to take medicines that suppress the immune system across the whole body, either within 14 days before starting the trial or during the trial.
- People who have had major surgery (not including minor procedures like needle biopsies) within 4 weeks before starting the trial, or who are expected to need major surgery during the trial.
- People who have cancer that has spread to the brain or the lining around the brain and spine, and is not currently under control.
- People who have a history of an autoimmune disease that has required treatment with steroids or immune-suppressing medicines.
- People who are trying to become pregnant, are currently pregnant, or are breastfeeding.
- People where the trial doctor believes participation may create additional health risks or affect the reliability of the trial results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Binghe Xu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: +86 13332895357
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants who experience one or more dose-limiting toxicities (DLTs); Maximum Tolerated Dose (MTD) of MR001; Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.